FDA Clears New Blood Test for Earlier Alzheimer’s Detection
The FDA has cleared a new blood test, ELECSYS pTAU217, developed by Roche and Eli Lilly, which can aid doctors in detecting Alzheimer's disease earlier in patients aged 55 and older experiencing cognitive decline. This development offers a new diagnostic…
Cleveland Akron, OH, August 26, 2026 —
A new blood test designed to aid in the earlier detection of Alzheimer’s disease has received clearance from the U.S. Food and Drug Administration (FDA). The test, known as ELECSYS pTAU217, is a collaborative development by Roche and Eli Lilly.
This diagnostic tool is intended for use in patients aged 55 and older who are experiencing cognitive decline. The ELECSYS pTAU217 test can help doctors identify potential indicators of Alzheimer’s disease, offering a new avenue for diagnosis and subsequent management planning.
The clearance of this test represents a significant development for healthcare providers and patients alike. Early detection of Alzheimer’s disease is considered crucial for potentially slowing disease progression and for allowing individuals and their families to make informed decisions about future care.
The availability of this new blood test is expected to benefit the Cleveland-Akron (Canton) region by providing a more accessible and potentially less invasive diagnostic option compared to some existing methods. Further details regarding the rollout and availability of the ELECSYS pTAU217 test in clinical settings were not immediately provided.
Story summarized from the original created by Jennifer Jordan on fox8.com, see more information here.
